



(Va)

wherein t is 1, 2 or 3.


4. A compound as claimed in any one of claims 1 to 3 wherein -NH-A-Y- is a divalent radical having one of the stereospecific formulae (B), (C), (D), (E), (F), (G), (H), (I) or (J), wherein Y is as defined with reference to formula (I):




(B)




(C)




(D)




(E)




(F)




(G)



(H)



(I)



(J)

5. A compound as claimed in claim 4 wherein Y is -O- .

6 A compound as claimed in claim 4 wherein -NH-A-Y- has formula (B), (C), (D), (E), (I) or (J) as defined in claim 4~~3~~ and wherein Y is -O-.

7. A compound as claimed in any of claims 1 to 6 wherein R^{4b} is isopropyl, cyclopentyl, or phenyl which is optionally substituted by one or two groups selected from C_1-C_6 alkyl, halogen and hydroxy.

8. A compound as claimed in any of claims 1 to 6 wherein R^{4b} is 2,6-dichlorophenyl, 2-chlorophenyl, or 2-hydroxyphenyl.

9. A compound as claimed in any of claims 1 to 6 wherein R^{3b} is methoxymethyl.

10. A compound as claimed in any of the preceding claims wherein R^2 is a group (IIIb) or (IIIc) wherein R^7 and R^8 are independently ethyl or methyl;

~~11. A compound as claimed in any of claims 1 to 9 wherein R^2 is a group (IIIb1) or (IIIb2).~~

~~12~~11. A pharmaceutical composition comprising a compound as claimed in any of the preceding claims, together with one or more pharmaceutically acceptable carriers.

~~13~~12. A composition as claimed in claim ~~12~~11, which is adapted for inhalation for pulmonary administration.

~~14~~13. A compound as claimed in any of claims 1 to 10~~11~~, for use in the treatment of a disease or condition which benefits from inhibition of p38 MAP kinase activity.

~~15~~14. A compound for use as claimed in claim ~~14~~13, wherein said disease or condition is selected from chronic obstructive pulmonary disease, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy or airways disease that is associated with pulmonary hypertension.